Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last $5.96 USD
Change Today +0.10 / 1.71%
Volume 1.1M
ACHN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 02/9/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

300 George Street

New Haven, CT 06511

United States

Phone: 203-624-7000

Fax: 203-624-7003

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The company is focusing its efforts on developing short-duration combination therapies for the treatment of chronic hepatitis C virus (HCV) infection that are once-daily and ribavirin-free. Primarily, the company is advancing combination regimens containing ACH-3102, a NS5A inhibitor, in phase II clinical development; ACH-3422, a NS5B nucleotide polymerase inhibitor, in phase I clinical development; and Sovaprevir, a NS3 protease inhibitor, in phase II clinical development. Drug Candidates ACH-3102, a NS5A Inhibitor The company is developing combination drug regimens that include ACH-3102, its pan-genotypic, second generation NS5A inhibitor. As of December 31, 2014, the company completed three phase IIa clinical trials with ACH-3102, including the -007 trial with sovaprevir; the -005 study, which examined the use of ACH-3102 with ribavirin alone; and the Proxy Doublet study, which examined the use of ACH-3102 in combination with sofosbuvir, a nucleotide NS5B polymerase inhibitor marketed by Gilead Sciences, Inc. under the brand name Sovaldi. ACH-3102 has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). ACH-3422, a NS5B Nucleotide Polymerase Inhibitor The company is seeking to develop combination drug regimens to address all HCV genotypes based on use of ACH-3422, its nucleotide prodrug inhibitor of HCV NS5B polymerase. ACH-3422 is tolerated in a phase Ib proof of concept study in which HCV patients receiving a once-daily 700mg dose of ACH-3422 for 14 days demonstrated mean maximal viral load reduction of 4.6 log10. Sovaprevir, a NS3 Protease Inhibitor The company has completed a phase II clinical trial that evaluated 12 weeks of treatment consisting of sovaprevir and the company’s NS5A inhibitor, ACH-3102, with ribavirin for the treatment of genotype 1 HCV (the -007 trial). In 2013, the FDA placed a clinical hold on sovaprevir after elevations in liver enzymes were noted in a phase I healthy subjects drug-drug interaction study evaluating the effects of concomitant administration of sovaprevir with ritonavir-boosted atazanavir. In 2014, the FDA lifted the full clinical hold, allowing the company to advance sovaprevir in clinical trials of HCV-infected patients, but requiring the company to seek FDA approval to conduct multi-dose clinical trials in healthy subjects. Following an internal assessment of the company’s protease inhibitor drug candidates, sovaprevir and ACH-2684, it determined to advance sovaprevir in future clinical trials with ACH-3422 and ACH-3102, rather than ACH-2684. The company plans to initiate a drug-drug interaction study with sovaprevir plus compounds that potentially impact active transport mechanisms in the liver and intestines in the first half of 2015. The company intends to continue to focus on the discovery and development of new drug candidates through its extensive expertise in biology and medicinal chemistry. Strategy The company’s strategy is to pursue patents, developed internally and licensed from third parties, and other means to otherwise protect its technology, inventions and improvements that are commercially important to the development of the company’s business. Research and Development The company incurred approximately $53.5 million in research and development costs for the year ended December 31, 2014. Intellectual Property The company has a license and development agreement with ORA, Inc. for the worldwide development and commercialization of ACH-702 delivered topically or locally. The company has a license agreement for elvucitabine with GCA Therapeutics, Ltd. (GCAT) for the treatment of both Hepatitis B and HIV infection. The license grants GCAT the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, to clinically develop and commercialize elvucitabine in mainland China, Hong Kong, and Taiwan. History Achillion Pharmaceuticals, Inc. was founded in 1998. The company was incorporated in 1998 in Delaware.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $5.96 USD +0.10

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 3,915 GBp +8.50
Bavarian Nordic A/S kr228.00 DKK -2.50
Chimerix Inc $6.72 USD +0.30
Emergent BioSolutions Inc $33.63 USD +0.55
PharmAthene Inc $1.71 USD +0.03
View Industry Companies
 

Industry Analysis

ACHN

Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.2x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ACHILLION PHARMACEUTICALS, please visit www.achillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.